文献速递消化系统肿瘤支持与姑息治疗

白蛋白结合型紫杉醇联合吉西他滨联合或不联合托珠单抗一线治疗晚期胰腺癌的随机II期研究:生存与恶病质

Randomized Phase II Study of Nab-Paclitaxel and Gemcitabine With or Without Tocilizumab as First-Line Treatment in Advanced Pancreatic Cancer: Survival and Cachexia.
PubMed 文献 · J Clin Oncol · 2025-05-12

这项随机II期试验比较吉西他滨/白蛋白结合型紫杉醇(Gem/Nab)联合或不联合抗IL-6受体抗体托珠单抗(Toc)一线治疗晚期胰腺癌的疗效。主要终点6个月总生存率两组无显著差异(68.6% vs 62.0%,P=0.409),但Toc组18个月生存率提高(27.1% vs 7.0%,P=0.001)且肌肉丢失减少,3级以上治疗相关不良事件增加。

要点

  • 主要终点未达到:6个月OS率Gem/Nab/Toc组68.6% vs Gem/Nab组62.0%(P=0.409)。
  • 18个月OS率Gem/Nab/Toc组27.1% vs Gem/Nab组7.0%(P=0.001),中位OS、PFS、ORR无差异。
  • Toc降低肌肉丢失(2个月中位变化+0.1013% vs -3.430%,P=0.0012),但3级以上TrAE增加(88.1% vs 63.4%,P<0.001)。

核心结论

  • 主要终点未达到且Toc增加治疗相关不良事件,但18个月生存率提高和肌肉消耗减少支持IL-6阻断具有独立于GDF15的抗恶病质效应。
  • 进一步研究可利用这些发现开展精准抗恶病质治疗。

研究设计与样本

  • 随机II期试验(ClinicalTrials.gov标识NCT02767557),比较Gem/Nab联合或不联合Toc一线治疗晚期胰腺癌。
  • 安全性队列接受Gem 1,000 mg/m2和Nab 125 mg/m2于第1、8、15天及Toc 8 mg/kg于第1天,每28天为一周期。
  • 改良Glasgow预后评分为1或2的参与者按1:1随机分配接受Gem/Nab/Toc或Gem/Nab。
  • 主要终点为6个月总生存率(OS6);次要终点为无进展生存期(PFS)、总缓解率(ORR)和安全性;探索性终点为恶病质、生活质量和生物标志物包括GDF15。
  • 共147例患者接受治疗,包括6例安全性队列参与者;中位随访期8.1个月(IQR,4.2-13.9)。

主要发现

  • OS6在Gem/Nab/Toc组为68.6%(95%CI,56.3至78.1),在Gem/Nab组为62.0%(49.6-72.1)(P=0.409)。
  • 18个月OS率Gem/Nab/Toc组 vs Gem/Nab组为27.1% vs 7.0%(P=0.001)。
  • 中位OS、PFS或ORR未见差异。
  • 3级以上治疗相关不良事件发生率Gem/Nab/Toc组为88.1%,Gem/Nab组为63.4%(P<0.001)。
  • Gem/Nab/Toc较Gem/Nab减少肌肉丢失:2个月中位变化+0.1013% vs -3.430%(P=0.0012),4个月+0.7044 vs -3.353(P=0.036);肌肉丢失发生率2个月43.48% vs 73.52%(P=0.0045),4个月41.82% vs 68.75%(P=0.0062)。

临床怎么用

  • 作者认为,尽管主要终点未达到且Toc增加治疗相关不良事件,18个月生存率提高和肌肉消耗减少支持IL-6阻断具有独立于GDF15的抗恶病质效应。
  • 作者提出进一步研究可利用这些发现开展精准抗恶病质治疗。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: This randomized phase-II trial (ClinicalTrials.gov identifier: NCT02767557) compared efficacy of gemcitabine/nab-paclitaxel (Gem/Nab) with or without the anti-interleukin-6 (IL-6) receptor antibody tocilizumab (Toc) for advanced pancreatic cancer (PC). METHODS: A safety cohort received Gem 1,000 mg/m2 and Nab 125 mg/m2 on days 1, 8, and 15, and Toc 8 mg/kg on day 1 for each 28-day cycle. Participants with modified Glasgow prognostic scores of 1 or 2 were randomly assigned 1:1 to receive Gem/Nab/Toc or Gem/Nab. The primary end point was the overall survival (OS) rate at 6 months (OS6). Secondary end points were progression-free survival (PFS), overall response rate (ORR), and safety. Exploratory end points were cachexia, quality of life, and biomarkers, including the cachexia-promoting protein, growth differentiation factor 15 (GDF15). RESULTS: Overall, 147 patients were treated, including six safety cohort participants. The median follow-up period was 8.1 months (IQR, 4.2-13.9). OS6 was 68.6% (95% CI, 56.3 to 78.1) for the Gem/Nab/Toc group and 62.0% (49.6-72.1) for the Gem/Nab group (P = .409). OS for Gem/Nab/Toc versus Gem/Nab improved at 18 months (27.1% v 7.0%, P = .001). No differences in median OS, PFS, or ORR were observed. Incidence of grade-3+ treatment-related adverse events (TrAEs) was 88.1% for Gem/Nab/Toc and 63.4% for Gem/Nab (P < .001). Gem/Nab/Toc decreased muscle loss versus Gem/Nab, with median change +0.1013% versus -3.430% (P = .0012) at 2 months and +0.7044 versus -3.353% (P = .036) at 4 months. Incidence of muscle loss was 43.48% on Gem/Nab/Toc versus 73.52% on Gem/Nab at 2 months (P = .0045) and 41.82% versus 68.75% (P = .0062) at 4 months. GDF15 was not changed by Gem/Nab or Gem/Nab/Toc. CONCLUSION: Although the primary end point was not met and TrAEs were increased by Toc, increased survival at 18 months and reduced muscle wasting support an anticachexia effect of IL-6 blockade independent of GDF15. Further studies could leverage these findings for precision anticachexia therapy.

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. Chen IM, Johansen JS, Theile S, et al. Randomized Phase II Study of Nab-Paclitaxel and Gemcitabine With or Without Tocilizumab as First-Line Treatment in Advanced Pancreatic Cancer: Survival and Cachexia. J Clin Oncol. 2025. PMID: 40354592. doi:10.1200/JCO.23.01965

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。